Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 inhibitor plus anlotinib neoadjuvant therapy for resectable stage II-III NSCLC
ChiCTR2100052565Phase 2Recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by Tianjin Medical University General Hospital. Primary endpoints: Major pathologic remission rate, Perioperative adverse events and 1 more. Started Nov 2021; status: recruiting.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100052565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052565.